细胞毒性T细胞
癌症研究
免疫系统
细胞内
CD8型
趋化因子
肺癌
免疫疗法
ICAM-1
化学
细胞间粘附分子
医学
免疫学
细胞生物学
生物
细胞粘附
细胞
内科学
生物化学
体外
作者
Se‐Hoon Lee,Yeongmin Kim,Bu‐Nam Jeon,Gihyeon Kim,Jinyoung Sohn,Youngmin Yoon,Sujeong Kim,Yun-Jae Kim,Hye Min Kim,Hongui Cha,Na‐Eun Lee,Hyunsuk Yang,Joo‐Yeon Chung,Areum Jeong,Yun Yeon Kim,Sang Gyun Kim,Yeonhee Seo,Sehhoon Park,Hyun Ae Jung,Jong‐Mu Sun
标识
DOI:10.1002/advs.202204378
摘要
Immune checkpoint inhibitor (ICI) clinically benefits cancer treatment. However, the ICI responses are only achieved in a subset of patients, and the underlying mechanisms of the limited response remain unclear. 160 patients with non-small cell lung cancer treated with anti-programmed cell death protein-1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) are analyzed to understand the early determinants of response to ICI. It is observed that high levels of intracellular adhesion molecule-1 (ICAM-1) in tumors and plasma of patients are associated with prolonged survival. Further reverse translational studies using murine syngeneic tumor models reveal that soluble ICAM-1 (sICAM-1) is a key molecule that increases the efficacy of anti-PD-1 via activation of cytotoxic T cells. Moreover, chemokine (CXC motif) ligand 13 (CXCL13) in tumors and plasma is correlated with the level of ICAM-1 and ICI efficacy, suggesting that CXCL13 might be involved in the ICAM-1-mediated anti-tumor pathway. Using sICAM-1 alone and in combination with anti-PD-1 enhances anti-tumor efficacy in anti-PD-1-responsive tumors in murine models. Notably, combinatorial therapy with sICAM-1 and anti-PD-1 converts anti-PD-1-resistant tumors to responsive ones in a preclinical study. These findings provide a new immunotherapeutic strategy for treating cancers using ICAM-1.
科研通智能强力驱动
Strongly Powered by AbleSci AI